<\/p>\n
Claribid is a clarithromycin tablet (250 mg \/ 500 mg, Abbott)<\/strong> \u2014 a macrolide antibiotic. First-line for H. pylori triple therapy (with PPI + amoxicillin), atypical pneumonia, and sinusitis. Strong CYP3A4 inhibitor \u2014 review concurrent statins, calcium-channel blockers, and ergot alkaloids before starting.<\/p>\n<\/div>\n \ud83d\udce6 Every order is covered by our Reshipment Assurance Policy<\/strong><\/a> \u2014 if your parcel does not arrive within 20 business days, we reship it.<\/p>\n Our generic medications are sourced from WHO-GMP certified manufacturers and shipped worldwide in discreet, plain packaging \u2014 no medication name on the parcel exterior. Card payments are routed through a regulated processor (statement descriptors include a regulated card-payment processor \u2014 never “MedsBase” or any medication name). Crypto and SEPA bank transfer are also accepted. Every order is backed by our Reshipment Assurance Policy.<\/p>\n Claribid contains Clarithromycin<\/strong>, a macrolide antibiotic that binds the 50S bacterial ribosomal subunit and blocks peptide-chain elongation, arresting bacterial protein synthesis. Macrolides are bacteriostatic at standard doses but bactericidal at higher concentrations against susceptible organisms. Spectrum includes Streptococcus species (including some penicillin-resistant pneumococci), Mycoplasma pneumoniae, Chlamydia trachomatis and pneumoniae, Legionella, Bordetella, and Helicobacter pylori. Activity against staphylococci is unreliable due to widespread macrolide resistance, and most Enterobacteriaceae are intrinsically resistant.<\/p>\n Clarithromycin has the most consistent Helicobacter pylori<\/em> activity of the macrolide class (where local resistance is < 15%) and is a key component of triple-therapy peptic-ulcer eradication regimens. It is a strong CYP3A4 inhibitor.<\/p>\nWhy order from MedsBase<\/h3>\n
How Claribid works<\/h2>\n
Indications & dosing<\/h2>\n